Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome
Journal of the Korean Neurological Association
;
: 709-714, 1994.
Article
Dans Coréen
| WPRIM
| ID: wpr-49787
ABSTRACT
High dose intravenous immunoglobulin (IVIg) therapy can improve the clinical course of several immune mediciated diseases. We evaluated clinical effects and side effects of IVIg in Guillain-Barre syndrome (GBS). 19 Patients with GBS were studied prospectively in a placebo-controlled trial. 11 Patients were received high dose IVIg (400mg/kg for 5 days) and controls received only conservative treatment. The disability scores using modified Rankin scores before and after treatment of each group were compared. Four weaks later, mean Rankin Score of IVIg group was 2.5 + 0.7 and control group was 3.3+ 0.5which showed significant difference(p<0.05). There were no serious advers effer of promote early improvement with safety in acute phase of Guillan-Barre syndrome.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Immunoglobulines
/
Études prospectives
/
Immunisation passive
/
Immunoglobulines par voie veineuse
/
Syndrome de Guillain-Barré
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Neurological Association
Année:
1994
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS